Black Diamond Therapeutics, Inc.
BDTXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BDTX. That does not mean none is planned.
Get an email about BDTX's next catalysts
Track Black Diamond Therapeutics (BDTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
BDTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.03 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
silevertinib (BDTX-1535) monotherapy
Non-Small Cell Lung Cancer
silevertinib in combination with temozolomide
Glioblastoma (GBM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
silevertinib (BDTX-1535) monotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
silevertinib in combination with temozolomide | Phase 2 | Glioblastoma (GBM) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Black Diamond Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Black Diamond Therapeutics, Inc.'s (BDTX) pipeline across Phase 2. Its lead program is silevertinib (BDTX-1535) monotherapy (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Black Diamond Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Black Diamond Therapeutics, Inc. (BDTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BDTX biotech catalysts?→
Add BDTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Black Diamond Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.